These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36596381)

  • 41. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S
    Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
    van den Brink EN; Ter Meulen J; Cox F; Jongeneelen MA; Thijsse A; Throsby M; Marissen WE; Rood PM; Bakker AB; Gelderblom HR; Martina BE; Osterhaus AD; Preiser W; Doerr HW; de Kruif J; Goudsmit J
    J Virol; 2005 Feb; 79(3):1635-44. PubMed ID: 15650189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.
    Peng L; Hu Y; Mankowski MC; Ren P; Chen RE; Wei J; Zhao M; Li T; Tripler T; Ye L; Chow RD; Fang Z; Wu C; Dong MB; Cook M; Wang G; Clark P; Nelson B; Klein D; Sutton R; Diamond MS; Wilen CB; Xiong Y; Chen S
    Nat Commun; 2022 Mar; 13(1):1638. PubMed ID: 35347138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
    Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant.
    Hingankar N; Deshpande S; Das P; Rizvi ZA; Wibmer CK; Mashilo P; Ansari MY; Burns A; Barman S; Zhao F; Mukherjee S; Torres JL; Chattopadhyay S; Mehdi F; Sutar J; Rathore DK; Pargai K; Singh J; Sonar S; Jakhar K; Dandotiya J; Bhattacharyya S; Mani S; Samal S; Singh S; Kshetrapal P; Thiruvengadam R; Batra G; Medigeshi G; Ward AB; Bhatnagar S; Awasthi A; Sok D; Bhattacharya J
    PLoS Pathog; 2022 Apr; 18(4):e1010465. PubMed ID: 35482816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.
    Lai GC; Chao TL; Lin SY; Kao HC; Tsai YM; Lu DC; Chiang YW; Chang SY; Chang SC
    Antiviral Res; 2022 Apr; 200():105290. PubMed ID: 35296418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail.
    Addetia A; Park YJ; Starr T; Greaney AJ; Sprouse KR; Bowen JE; Tiles SW; Van Voorhis WC; Bloom JD; Corti D; Walls AC; Veesler D
    Cell Rep; 2023 Jun; 42(6):112621. PubMed ID: 37300832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge.
    Liu Q; Zhao H; Li Z; Zhang Z; Huang R; Gu M; Zhuang K; Xiong Q; Chen X; Yu W; Qian S; Zhang Y; Tan X; Zhang M; Yu F; Guo M; Huang Z; Wang X; Xiang W; Wu B; Mei F; Cai K; Zhou L; Zhou L; Wu Y; Yan H; Cao S; Lan K; Chen Y
    Signal Transduct Target Ther; 2023 Sep; 8(1):347. PubMed ID: 37704615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
    Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
    J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2.
    Antipova NV; Larionova TD; Siniavin AE; Nikiforova MA; Gushchin VA; Babichenko II; Volkov AV; Shakhparonov MI; Pavlyukov MS
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein.
    Otsubo R; Minamitani T; Kobiyama K; Fujita J; Ito T; Ueno S; Anzai I; Tanino H; Aoyama H; Matsuura Y; Namba K; Imadome KI; Ishii KJ; Tsumoto K; Kamitani W; Yasui T
    Sci Rep; 2022 Nov; 12(1):20120. PubMed ID: 36418391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
    Favorskaya IA; Shcheblyakov DV; Esmagambetov IB; Dolzhikova IV; Alekseeva IA; Korobkova AI; Voronina DV; Ryabova EI; Derkaev AA; Kovyrshina AV; Iliukhina AA; Botikov AG; Voronina OL; Egorova DA; Zubkova OV; Ryzhova NN; Aksenova EI; Kunda MS; Logunov DY; Naroditsky BS; Gintsburg AL
    Front Immunol; 2022; 13():822159. PubMed ID: 35281053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes.
    Zadeh SMM; Bayat AA; Shahsavarani H; Karimi-Busheri F; Kiani J; Ghods R; Madjd Z
    Virol J; 2024 Feb; 21(1):37. PubMed ID: 38317249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model.
    Peter AS; Roth E; Schulz SR; Fraedrich K; Steinmetz T; Damm D; Hauke M; Richel E; Mueller-Schmucker S; Habenicht K; Eberlein V; Issmail L; Uhlig N; Dolles S; Grüner E; Peterhoff D; Ciesek S; Hoffmann M; Pöhlmann S; McKay PF; Shattock RJ; Wölfel R; Socher E; Wagner R; Eichler J; Sticht H; Schuh W; Neipel F; Ensser A; Mielenz D; Tenbusch M; Winkler TH; Grunwald T; Überla K; Jäck HM
    Eur J Immunol; 2022 May; 52(5):770-783. PubMed ID: 34355795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
    Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X
    J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.